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By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued
in 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-
therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was also
recommended in responding patients. In patients relapsing after an interval longer than 12 months from
frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by
rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was
recommended for young fit patients who achieve a response after salvage chemoimmunotherapy. Am. J.
Hematol. 88:185–192, 2013. VC 2012 Wiley Periodicals, Inc.
Introduction
Follicular cell lymphoma (FL) is a frequent disorder for
which several treatment options have been recently
proposed. In order to promote widespread adoption of
appropriate clinical practice, the Italian Society of Hematol-
ogy (SIE), and the affiliate societies SIES (Societa` Italiana
di Ematologia Sperimentale) and GITMO (Gruppo Italiano
Trapianto Midollo Osseo) established regular updating of
published guidelines. Previous guidelines addressed indo-
lent non-Hodgkin’s lymphomas (NHL) [1], but more recently,
specific treatment options were devoted to FL; therefore,
current guidelines are specifically directed to the manage-
ment of FL. In the 2008 WHO classification, grade 3b FL
were separated and are universally treated as diffuse large
B-cell lymphoma (DLBCL) [2]. Therefore, the present guide-
lines targeted grade 1-2-3a FL. We used the GRADE
(grades of recommendation, assessment, development,
and evaluation) system [3], which is based on a sequential
assessment of the quality of evidence followed by an analy-
sis of the benefit-risk balance and subsequent judgment
about the strength of recommendations.
Methods
Guidelines development process. The Advisory Council (AC), com-
posed of three members with expertise in clinical epidemiology, hema-
tology, and critical appraisal, oversaw the process. An Expert Panel
(EP) was selected according to the conceptual framework elements of
the NIH Consensus Development Program [4]. During a first meeting,
the EP decided which clinical issues needed an update and the AC
checked which clinical queries might be addressed by a critical
appraisal of evidence [3].
Producing and grading evidence-based recommendations. The AC
selected the clinical questions that needed to be addressed by a critical
appraisal of evidence. The EP chose the critical outcomes for each
clinical query. Literature search was performed in July 2011 and limited
to English-language publications edited after 2005. The search included
proceedings 2009 through 2010 of the American Society of Hematol-
ogy, the European Hematology Association, and the 11-ICML (11th
International Conference on Malignant Lymphoma). According to
GRADE methodology [3], the AC prepared ‘‘evidence tables’’ and
‘‘quality of evidence tables’’ (available by the corresponding author on
request) for each critical appraisal. The EP received the critical apprais-
als and was asked to draft recommendations based on the benefit to
risk profile of each compared intervention. Definite agreement of the
recommendations and of their strength (weak or strong) was made
through subsequent face-to-face meetings.
Producing consensus-based recommendations. The consensus
methodology was applied by the EP for all the issues worth to be
updated but not addressable by a critical appraisal. During three
consecutive consensus conferences, the issues were analyzed and dis-
cussed according to the nominal group technique, as previously
described [5].
Results
Issue 1: Staging (consensus-based recommendations)
FL is a (18)F-FDG avid disease, since more than 90% of
patients with FL show a PET positive disease and sensitiv-
ity of staging PET is usually higher than 95% [6–9]. Pub-
lished literature includes 10 retrospective analyses [9–18]
and 1 prospective one [19]: pooled analysis of 356 patients
revealed that 24% were upstaged from Stage I–II to Stage
III–IV. Baseline PET also showed to have a high prognostic
value, irrespective of FLIPI [10,11,17,19]. No study
reported the clinical outcomes in patients in which the ther-
apy was adjusted according to a PET-staged disease. The
assessment of bone marrow involvement by PET is not reli-
able due to low sensitivity [8,9,20]. Globally, the analyzed
studies showed a moderate quality.
The predictive role of pretreatment BCL2/IgH levels in
bone marrow and peripheral blood is still controversial. In a
seminal study, Rambaldi et al. [21] showed that the pres-
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ence of less than 1/1,000 BCL2/IgH (1) cells in the bone
marrow was the best predictor of complete response after
first-line treatment and levels less than 1/100 a good pre-
dictor of five-year event-free survival (EFS). However, this
result has not been validated, and in 238 patients with re-
fractory-relapsed FL enrolled into the EORTC 20981 phase
III trial, a BCL2 positive bone marrow was associated with
a worse progression-free survival (PFS) but the BCL2/IgH
levels were not correlated with the rates of post-induction
response [22]. However, recognizing that FLIPI was vali-
dated in the prerituximab era [23], a FLIPI 2 score including
age, serum beta2 microglobulin, hemoglobin concentration,
bone marrow involvement and tumor burden correlating
with the longest diameter of the largest involved lymph
node was recently proposed [24]. Both indexes have not
been validated in prospective trials; therefore, they cannot
be used to inform treatment decision in clinical trials.
Recommendations Appropriate staging is a fundamental
step in the initial approach to patients with FL. Initial work-
up should include a CT scan of the neck, thorax, abdomen
and pelvis, and a bone marrow biopsy. FL is a FDG avid
disease and PET allows the identification of a higher num-
ber of nodal and extranodal areas compared with CT scan.
PET scan should be included in staging of patients with lim-
ited-stage disease at CT scan and possibly candidates to
radiotherapy only. The panel agreed that PET upstaged
patients should receive a therapy according to the new
stage, even though there is no evidence that this choice is
able to improve the outcome of the disease.
Pretreatment PET is also advisable to allow an optimal
assessment of response for those patients needing chemother-
apy in which an early stage disease (i.e., Stage II) and therapy
fitness make the probability of CR high. Staging should be
assigned according to the Ann Arbor system. Bone marrow bi-
opsy histology should be performed with monolateral upper
posterior iliac spine biopsy of at least 20 mm length and should
include appropriate immunohistochemistry for the lymphoma-
tous tissue. A complete blood count and routine blood chemis-
try including LDH, beta2microglobulin and uric acid are
required. Like for all patients’ candidate to receive cytotoxic
and/or immunomodulatory drugs, screening for main infectious
diseases, including HIV and hepatitis B and C, is recom-
mended. Bone marrow and peripheral blood tests with polymer-
ase chain reaction for t(14;18) chromosomal translocation and/
or for immunoglobulin gene rearrangement (Ig CDR3) is not
recommended for routine assessment and outside clinical trials.
A follicular lymphoma international prognostic index (FLIPI) (>4
nodal sites, elevated LDH, age >60 years, Stage III–IV, hemo-
globin <12 g/dl) should be determined in all the patients.
Issue 2: When to start treatment (consensus-based
recommendations)
Based to the lack of overall survival (OS) improvement
after treatment of asymptomatic advanced-stage patients
[25], and according to the previous SIE guideline edition [1]
and to GELF data [26], the panel agreed on the following
recommendations.
Recommendations Treatment can be started in patients
with Stage II–IV disease in case of one of the following fea-
tures occurs: systemic symptoms, high tumor burden (i.e.,
>3 lymph nodes measuring >3 cm or a single lymph node
>7 cm), extranodal disease, cytopenia due to marrow
involvement, spleen involvement (516 cm by CT), leukemic
phase, serous effusion, symptomatic or life endangering
organ involvement, rapid lymphoma progression, consis-
tently increased LDH levels. A policy of watchful waiting is
not recommended in patients with Stage I–II disease, with
the exception of patients with a short life expectancy due to
severe comorbidity or with contraindications to therapy.
Issue 3: First line therapy (evidence–based recommen-
dations)
In asymptomatic stage II–IV non bulky patients is rit-
uximab alone better than watchful waiting? With the
advent of rituximab and its relatively favorable side effect
profile, a randomized trial compared watchful waiting with
rituximab 375 mg/m2 weekly for 4 consecutive weeks fol-
lowed by rituximab maintenance every 2 months for 2 years
[27] in 462 asymptomatic patients. Time for initiation of
new therapy was significantly improved in the maintenance
group in comparison with the watchful group: at 3 years 52
versus 9% of patients required treatment (HR, 0.20; 95%
CI 0.13–0.29; P 5 0.001). PFS was also significantly
improved (81 vs. 33% at 3 years) by rituximab maintenance
(HR, 0.21; 95% CI 0.15–0.29; P 5 0.001). No statistically
significant difference in OS was detected. Quality of life
appeared to be ameliorated in patients receiving rituximab
[28]. The panel agreed that improvement in long-term sur-
vival was the critical endpoint to be considered in this set-
ting and that more evidence is needed before recommend-
ing rituximab in asymptomatic patients.
Recommendations For asymptomatic Stage II–IV, non
bulky patients watchful waiting remains the standard of
care and rituximab cannot be recommended (quality of evi-
dence, low; strength of recommendation, weak).
In patients with stage I–II disease, which dose of
radiotherapy is recommended? Involved field radiother-
apy (IF-RT) remains the recommended treatment for
patients with limited stage disease, as detailed in our previ-
ous guidelines [1]. A recent randomized trial compared 40–
45 Gy with 24 Gy radiotherapy in 661 sites in patients with
indolent NHL, predominantly follicular, reporting no differ-
ence in the major outcomes, which is response rate, PFS
and OS [29].
Recommendations Patients with Stage I–II disease, a low
tumor burden, and with documented contiguity of involved
lymph-nodes treatable in the same radiotherapy field,
should receive external involved field radiotherapy, at the
dose of 24 Gy (quality of evidence, low; strength of recom-
mendation, strong).
In patients with stage II–IV deserving treatment, is
chemoimmunotherapy better than chemotherapy? Che-
moimmunotherapy with rituximab was recommended for
patients candidates to chemotherapy in our previous guide-
lines [1]. Four randomized trials [30–33] comparing chemo-
immunotherapy with rituximab to chemotherapy without rit-
uximab in naı¨ve patients with FL Stage III–IV were
selected. A pooled analysis was performed on the critical
endpoints, that is, OS, failure free survival (FFS) and
severe infections (Fig. 1). OS (HR, 0.59; 95% CI 0.44–
0.79) and FFS improved (HR, 0.54; 95% CI 0.44–0.66).
However, no relevant increase of severe infections was
shown. Stage I–II patients with a high tumor burden were
not enrolled into the above trials, but in absence of new evi-
dence, the panel maintained the recommendation of the
previous version of the guidelines [1], and agreed that
patients with Stage II disease and high tumor burden, or
FLIPI >2 should receive frontline chemoimmunotherapy.
Recommendations Patients with Stage III–IV should receive
front-line chemoimmunotherapy. No evidence indicates che-
moimmunotherapy in Stage II disease. However, the panel
agreed that these patients should receive chemoimmuno-
therapy when there is high tumor burden or high-risk scor-
ing system (quality of evidence, moderate; strength of
recommendation, strong).
In patients candidates to frontline chemoimmuno-
therapy, which chemotherapy regimen should be
chosen? Two randomized trials comparing different chemo-
therapy regimens associated with rituximab are available
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for analysis; however, both have been reported only in
abstract form. Federico et al. in the FOLL05 trial compared
R-CVP versus R-CHOP versus R-FM in a homogenous FL
population of 534 patients [34]. A trend to longer 3 year
PFS and a significant amelioration of time to treatment fail-
ure was noted in the patients treated with R-CHOP and R-
FM. However, a higher rate of adverse events was shown
with R-FM compared to the other two treatment schedules.
A preliminary GRADE table could be built based on the
data reported by the oral presentation. Rummel et al.
tested R-bendamustine versus R-CHOP in a heterogene-
ous population of 513 patients, half of which had a FL while
the remaining patients had a diagnosis of either mantle cell
lymphoma or non-FL indolent lymphoma [35]. In the R-
bendamustine group PFS was prolonged from 35 to 55
months compared to R-CHOP (HR, 0.57; 95% CI 0.43–
0.77). Moreover, R-bendamustine had a lower rate of
Grade 3–4 adverse events compared to R-CHOP. In elderly
unfit patients several therapeutic options have been tested
in phase II or retrospective studies: rituximab monotherapy,
chlorambucil and rituximab, abbreviated chemoimmunother-
apy. However, no randomized study is available to guide
therapeutic decision. No GRADE table could be built based
on the subset of data reported by the abstract.
Recommendations There is evidence that many frontline
chemotherapy regimens, whether antracycline-based poly-
chemotherapy (CHOP or CHOP like regimens) or fludara-
bine-based polychemotherapy, or CVP regimen or benda-
mustine can be used in association with rituximab (quality
of evidence, low; strength of recommendation, weak).
In patients candidates to frontline chemoimmuno-
therapy, high-dose chemoimmunotherapy with autolo-
gous stem cell support is better than standard
chemoimmunotherapy? The impact of high-dose therapy
and autologous hematopoietic stem cell transplantation
(HSCT) versuss conventional-dose chemotherapy in the
management of FL has been faced by a systematic review
of the randomized clinical trials addressing the question
[36]. Seven trials proved eligible, four of which provided
data from 941 patients that could be included in a meta-
analysis and three of which remain unpublished. The
results suggest that high-dose therapy and autologous SCT
as part of FL initial treatment does not improve OS.
In the post-rituximab era, only one trial compared high-
dose therapy and autograft with R-CHOP: 136 patients with
untreated advanced FL Grades 1–3 were randomized
either to six cycles of R-CHOP or to R-HDS schedule [37].
The R-HDS consisted of two cycles of APO regimen (dox-
Figure 1. Result of the pooled analysis on the critical endpoints (overall survival, failure free survival, and severe infections) of the three published trials comparing che-
moimmunotherapy with rituximab the chemotherapy without rituximab in patients with follicular lymphoma Stage III–IV. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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orubicin, vincristine, and prednisone totaling 75 mg/sqm of
doxorubicin administration); patients not achieving complete
remission (CR) received two additional DHAP; the high-
dose phase consisted of 2 g/sqm etoposide followed by
two rituximab doses; afterwards 7 g/sqm of cyclophospha-
mide were delivered followed again by two rituximab doses;
eventually mitoxantrone 60 mg/sqm and melphalan 180
mg/sqm followed by autologous HSCT were administered.
CRs were 62% following R-CHOP and 85% following R-
HDS (P < 0.001). Four years projected values for EFS
were 28% for R-CHOP and 61% for R-HDS (P < 0.001).
Four years projected values for PFS were 31% for
R-CHOP and 68% for R-HDS (P < 0.001). OS was similar
in the two arms (R-CHOP, 80%; R-HDS, 81%). The cumu-
lative incidence of sMDS/AML at 4 years was 6.6% for
R-HDS and 1.7% for R-CHOP (P 5 0.111). A total of 26
non-fatal grades III to IV extra-hematologic early toxicities
occurred in the R-HDS arm compared to a total of seven
registered in the R-CHOP arm (P < 0.001).
Recommendation Upfront high-dose chemoimmunotherapy
with autologous stem cell support cannot be recommended
(quality of evidence, low; strength of recommendation,
strong).
Issue 4: Assessment of response (consensus-based
recommendations)
The independent prognostic significance of PET-CT per-
formed at the end of induction therapy has been recently
confirmed [38]; irrespective of conventional response [39],
PET positivity was associated with a reduced PFS (33 vs.
71%) and an increased risk of death (HR, 7.0; P 5 0.001).
However, no study addressed the management of patients
with discordant CT and PET results. Therefore, therapeutic
decisions cannot be actually based on PET results. The
prognostic role of molecular response is controversial, even
though any residual positivity at the end of a rituximab con-
taining program is associated with a remarkably poor out-
come [21]. The prognostic role of BCL2/IGH levels after
induction treatment still needs to be assessed in patients
receiving rituximab maintenance.
Recommendations Clinical response to first-line therapy
should be assessed according to revised IWG criteria [40].
Even though there is preliminary evidence that the best
response evaluation includes PET, the panel did not reach a
consensus on the extensive use of PET in response assess-
ment. The panel agreed that PET could be indicated in
patients in which the intention of therapy is achieving CR.
There is no evidence to support interim PET for guiding
treatment decisions. PET is not recommended for routine
use in the follow-up setting. The assessment of molecular
response is not recommended for routine assessment.
Issue 5: Post-induction therapy (evidence-based
recommendations)
In patients with at least partial response after first-
line chemoimmunotherapy, is maintenance with rituxi-
mab better than watchful waiting? The panel agreed that
improvement in PFS was the critical endpoint to be consid-
ered in this setting. The PRIMA study [41] randomized
1019 FL patients responsive to R-CHOP or RCVP to obser-
vation or rituximab maintenance (12 infusions of 375 mg/
sqm given intravenously one every 8 weeks) starting 8
weeks after the last induction treatment. Three-year PFS
was 74.9% (95% CI 70.9–78.9) in the rituximab mainte-
nance group and 57.6% (95% CI 53.2–62.2) in the obser-
vation group (stratified log rank, P 5 0.0001). The HR for
risk of progression was significantly in favor for the rituxi-
mab maintenance group (HR, 0.55; 95% CI 0.44–0.68).
Conversion from PR to CR was documented in 44% of the
patients. No significant difference in mortality was reported
in the two groups. Grades 3–4 adverse effects were 24% in
the rituximab group and 17% in the observation group (RR,
1.46; 95% CI 1.14–1.87). Grades 3–4 neutropenia was 1%
in the observation group and 4% in the maintenance group.
Grades 3–4 infections were 1% in the observation group
and 4% in the maintenance group. No statistical difference
was documented in quality of life between the two groups.
Recommendations Maintenance therapy with rituximab is
recommended in patients who reach at least a partial
response at the end of first-line therapy (quality of evi-
dence, high; strength of recommendation, strong).
In patients who achieved partial response after
first-line chemoimmunotherapy, is consolidation with
radioimmunoconjugates an option? Four hundred and
fourteen patients were enrolled in a multicenter randomized
trial (FIT trial) testing ibritumomab tiuxetan consolidation
after response (PR or CR) to first-line chemotherapy in FL
Stage III–IV compared to observation [42]. Radioimmuno-
therapy (RIT) consolidation converted 77% of patients who
were in PR after induction therapy to CR (P < 0.001). After a
median follow-up of 3.5 years, median PFS was 36.5 months
in the RIT group and 13.3 months in the control group (HR,
0.465; P < 0.0001). At follow-up, there was no difference in
OS between the two groups. Grades 3–4 infections were 8%
in the RIT arm compared to 2.4% in the control group. The
trial, however, enrolled only 15% of patients receiving rituxi-
mab as part of the induction regimen. This conclusion is fur-
ther supported by several phase II studies where ibritumo-
mab tiuxetan was given to patients after remission induction
with R-CHOP [43,44] or FNR [45,46].
Recommendations Ibritumomab tiuxetan proved to prolong
progression free survival in patients achieving partial
response after first-line chemoimmunotherapy. However,
the lack of comparison between ibritumomab tiuxetan and
rituximab maintenance does not allow to produce recom-
mendations on radioimmunotherapy in this setting (quality
of evidence, low; strength of recommendation, weak). The
panel claimed to be important to have a randomized study
evaluating the role of radioimmunotherapy versus rituximab
maintenance in patients who achieved a response after
first-line chemoimmunotherapy.
Issue 6: Relapsed/refractory patients (evidence-based
recommendations)
In patients relapsing after first line chemoimmuno-
therapy and requiring treatment, is rituximab and
chemotherapy reinduction superior to chemotherapy
alone? A trial randomized 465 FL patients relapsed after
first-line chemotherapy not including rituximab to either
R-CHOP or CHOP [47]. R-CHOP induction yielded an
increased CR rate compared to CHOP therapy (CHOP,
15.6%; R-CHOP, 29.5%; P > 0.001). At a median follow-up
of 33 months, patients treated with R-CHOP had signifi-
cantly longer median PFS (33 vs. 20 months) from first ran-
domization (HR, 0.65; P < 0.001). A slight non significant
increase of Grade 3–4 neutropenia was reported in the
R-CHOP arm (55 vs. 48%).
Recommendations In fit patients relapsing after first-line
chemoimmunotherapy and requiring treatment, rituximab
should be added to chemotherapy as reinduction, provided
there is no evidence of resistance to rituximab (quality of
evidence, low; strength of recommendation, weak).
In patients relapsing after first-line chemoimmuno-
therapy and achieving a response to reinduction rituxi-
mab and chemotherapy, is rituximab maintenance
better than observation? Van Oers et al. [47] randomly
assigned relapsing/resistant patients after R-CHOP or
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CHOP to either observation or maintenance with single
agent rituximab 375 mg/m2 once every 2 months for a max-
imum of 2 years. When CHOP 1 rituximab was used for
induction, the median PFS from second randomization for
patients who received rituximab maintenance therapy was
4.4 years compared with 1.9 years (HR, 0.69; P 5 0.43).
When CHOP only was used for induction, these figures
were, respectively, 3.1 years versus 1 year in the observa-
tion arm (HR, 0.37; P < 0.001). For patients in CR, median
PFS was 4.4 years in the rituximab maintenance arm ver-
sus 1.2 years in the observation arm (HR, 0.48; P 5
0.003). The last median follow-up [21] of 6 years showed
that maintenance rituximab significantly improved median
PFS (3.7 vs. 1.3 years; HR, 0.55), but was associated with
a significantly higher rate of severe (Grades 3–4) infection
(9.7 vs. 2.4%; P 5 0.01). There was a non significant trend
towards improved OS at 5 years with maintenance (74 vs.
64%; P < 0.07). Seven out of 167 patients withdrew from
maintenance treatment because of toxicity: four had
recurrent infections, one had severe neutropenia, one had
ventricular arrythmia, and one had persistent general com-
plaints. There were no deaths related to maintenance treat-
ment. Three other randomized trials assessed rituximab
maintenance in relapsed FL patients [48–50]. However, the
studies enrolled patients with refractory FL, mantle cell lym-
phoma or other indolent NHL. Moreover, no chemotherapy
reinduction was applied in two trials [49,50]. All the above
studies were reported by a Cochrane systematic review
[51]. Meta-analysis of the four available randomized trials
reported that OS was significantly ameliorated (HR, 0.58;
95% CI 0.42–0.79) while also infection and severe infec-
tions were increased (HR, 1.99; 95% CI 1.24–6.76).
Recommendations In patients relapsing after first-line che-
moimmunotherapy and achieving a response to reinduction
rituximab and chemotherapy, rituximab maintenance is
recommended (quality of evidence, low; strength of recom-
mendation, weak).
Relapsed/refractory patients (consensus-based
recommendations)
Which role for autologous HSCT? Two retrospective
studies [52,53] analyzed the outcomes of patients treated
with autologous HSCT or chemotherapy or chemoimmuno-
therapy in patients progressed or relapsed FL. Other
cohorts assessed the role of autologous HSCT in rituximab
pretreated patients [37,54–59]. The efficacy of rituximab
prior to stem cell collection as in vivo purging has been
tested by a randomized trial [60]. A retrospective analysis
conducted by the Gruppo Italiano Terapie Innovative nei
Linfomi (GITIL) reported the results of addition of rituximab
pre-HSCT [54]. Rituximab maintenance after autologous
HSCT was also assessed [60]. Several design limitations
restrict the applicability of the trial results to the indication
of autologous SCT in patients relapsed or refractory. So the
panel provided consensus based-recommendations.
Recommendations Autologous HSCT is recommended in
young (<65-year old) fit patients relapsing within 12 months
from the end of frontline chemoimmunotherapy and achiev-
ing a response to chemoimmunotherapy reinduction. Auto-
logous HSCT is a therapeutic option in young (<65-year
old) fit patients relapsing after at least 12 months from the
end of frontline chemoimmunotherapy and achieving a
response to chemoimmunotherapy reinduction. No suffi-
cient evidence support universal rituximab maintenance in
patients achieving a response after autologous HSCT.
Which role for allogeneic HSCT? Khouri [61] recently
reported the 8-year experience with the fludarabine (30 mg/
m2 on days –5 –3), cyclophosphamide (750 mg/m2 on days
(3–5) and rituximab (375 mg/m2 on day 13; 1,000 mg/m2 on
days –6, 11 and 18) (FCR ) regimen in 47 chemosensitive
FL patients treated with sibling donor (n 5 45) or matched
unrelated donor (n 5 2). With a median follow-up of 60
months PFS and OS were 83% and 85%, respectively. Non
relapse mortality (NRM) accounted for 15% of the patients.
Pinana et al. [62] described the long term outcome of 37 FL
patients with median age of 50 years (range 34–62 years) en-
rolled in two prospective protocols between 1999 and 2007.
Patients with relapsed or refractory FL were treated with a
conditioning regimen based on fludarabine (125–150 mg/m2)
combined with melphalan (80–140 mg/m2). With a median
follow-up of 52 months (range, 0.6–113 months), DFS at 4
years for patients with PD, PR or CR at transplantation were
29, 48, and 64%, respectively. The 4-year cumulative inci-
dence of nonrelapse mortality were 71, 33, and 26%, respec-
tively. Thomson et al. [63] reported the results of 82 consecu-
tive patients with relapsed or refractory FL conditioned for
allogeneic HSCT with alemtuzumab (20 mg on days –8 to –4)
combined with fludarabine (30 mg/m2 on days –7 to –3) and
melphalan (140 mg/m2 on day –2). With a median follow-up
of 43 months the NRM was 15% at 4 years. Risk of relapse
was 26%. At 4 years, the OS rate was 76%.
The EBMT Group reported a retrospective analysis on 44
matched unrelated donor stem cell transplantation (MUD-
SCT) for relapsed or refractory FL. Compared to myeloabla-
tive conditioning regimens, RIC showed on multivariate anal-
ysis reduced NRM and significantly longer PFS and OS [64].
Hari et al. [65] compared retrospectively the outcomes of
208 FL patients (27–70 years) treated either with myeloa-
blative conditioning (n 5 120) or reduced intensity condi-
tioning (n 5 88) before an HLA-identical sibling allogeneic
HSCT. There were no significant difference in 3-year PFS
or OS between the two cohorts. On multivariate analysis,
an increased risk of disease progression after RIC was
observed (RR, 2.97, P 5 0.04).
Recommendations Young (<65-year old) fit patients who
relapsed after or were refractory to a previous therapy
including autologous SCT are candidates to allogeneic SCT.
The availability of a compatible donor and the patient
preference should be considered in making this decision
Which role for radioimmunoconjugates? The efficacy
and safety of radiolabelled ibritumomab tiuxetan (single
dose of 14.8 MBq/Kg) and tositumomab in patients with re-
fractory/relapsed indolent NHL were compared with rituxi-
mab (375 mg/sqm once weekly for 4 weeks) and unlabelled
tositumomab, respectively, in two randomized trials [66,67].
Response rates ranged from 55 to 86% and CRs were
achieved in more than 30% of the patients. Higher response
rates, longer TTP and fewer adverse effects were observed
by retrospective analyses of patients receiving ibritumomab
tiuxetan or tositumomab as a second line therapy versus
third or further lines [68,69].
Recommendations The panel argued that for relapsed/re-
fractory patients, treatment with radioimmunoconjugates is
a therapeutic option. This should apply for those patients
non eligible to high-dose chemotherapy and HSCT.
Discussion
At present, several treatments are available for FL but
the information derived from literature may not fit with
relevant clinical questions, and the endpoints and/or the
population of patients included in trials are not always those
relevant in the clinical practice. In this project, aimed at
revising the guidelines for management of FL issued in
2005, we made specific evidence-based recommendations
for the most relevant key issues according to the GRADE
methodology, which imposes a preliminary judgment of the
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quality of evidence and a subsequent assessment of the
strength of the recommendation based on a qualitative risk-
benefit analysis. Also other institutions recently produced or
updated evidence-based guidelines for the management of
FL (NCCN, BCSH, ESMO) [70–72] (Table I). Systematic
reviews and consensus conferences addressed to specific
therapeutic issues, such as HSCT [73] and radioimmuno-
therapy [74] have also been published. The majority of pro-
duced recommendations in our project are common to the
above guidelines: in particular, several chemotherapy regi-
mens are accepted for association with rituximab in front-
line therapy of symptomatic advanced stage disease. In
deciding the best frontline therapy, we grounded our deci-
sion on the resulting efficacy and safety evidence. However,
the economic impact of frontline chemoimmunotherapy was
also assessed in several studies, and R-CVP resulted cost-
effective versus CVP [75–77], and R-CHOP versus CHOP
[77]. Moreover, rituximab maintenance after chemoimmuno-
therapy was associated with an incremental cost per QALY
gained of €12,600 to €18,147 versus R-CHOP followed by
observation [78,79]. The guidelines issued in the last year,
however, showed discrepancies about recommendations on
radioimmunoconjugates and HSCT. Indeed, the available
evidence for such therapies is low-level due to indirectness
in available randomized studies and to lack of randomized
studies. The results of ongoing trials investigating new ther-
apeutic modalities and novel agents will probably modify
the treatment management of FL in the next years. Thus,
we have planned to update the present guidelines by the
end of 2015.
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